| Subject: | FDA Approves New Drug for Treatment of Diabetes |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 10 May 2005 - 10:00 am |
| The FDA announced approval of the drug Symlin (pramlintide acetate) for the treatment of Type I and II diabetes patients. Symlin is an injectable a synthetic analog of human amylin which is a naturally occurring hormone that is produced in the beta cells of the pancreas that are the same cells that make insulin. Symlin is prescribed for patients with Type I diabetes, as an adjunct treatment for those patients who use mealtime insulin therapy and who have failed to achieve desired glucose... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert!® Virtual Compliance Administrator™ keeps clients informed by email of any changes to Federal regulations, including Joint Commission (TJC, formerly JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG, and many more, and also provides downloadable tools to ensure compliance. StayAlert! is a premium product sold as an annual site-license subscription. With the site license, the client can sign up an unlimited number of users for the email alerts and access to the StayAlert! online regulatory library. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
